Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned a consensus rating of “Hold” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $8.63.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in FULC. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Fulcrum Therapeutics during the third quarter valued at approximately $474,000. Intech Investment Management LLC purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter valued at $62,000. Charles Schwab Investment Management Inc. boosted its holdings in Fulcrum Therapeutics by 223.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after buying an additional 393,202 shares during the period. Walleye Capital LLC purchased a new stake in Fulcrum Therapeutics in the 3rd quarter worth $59,000. Finally, Verition Fund Management LLC bought a new stake in Fulcrum Therapeutics during the third quarter valued at about $134,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Price Performance

FULC stock opened at $3.21 on Tuesday. Fulcrum Therapeutics has a 1 year low of $2.78 and a 1 year high of $10.13. The company has a market cap of $173.27 million, a P/E ratio of -10.35 and a beta of 2.20. The stock’s fifty day moving average price is $3.60 and its 200-day moving average price is $3.84.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.